Isoproterenol Pharmacokinetics and Clinical Use
Introduction to Isoproterenol
- The American Heart Association acknowledges that isoproterenol has an elimination half-life of approximately 2-5 minutes when administered intravenously, making it an extremely short-acting agent that requires continuous infusion for sustained effect 1
Pharmacokinetic Properties
- The distribution half-life of isoproterenol is approximately 40 minutes, while the elimination half-life is 4.5 hours for the related compound treprostinil, but isoproterenol itself has a much shorter elimination half-life of 2-5 minutes, according to the American College of Cardiology 1
- The ultra-short half-life of isoproterenol explains why it must be administered as a continuous infusion rather than intermittent boluses for sustained chronotropic and inotropic effects, as recommended by the American College of Cardiology 2, 3
Clinical Implications
- The 2-5 minute half-life means that if an isoproterenol infusion is accidentally discontinued, the patient is at immediate risk for acute rebound deterioration, particularly in patients with severe bradycardia or pulmonary hypertension, as noted by the American Heart Association 1
Dosing Context
- For symptomatic bradycardia, isoproterenol is administered as 20-60 mcg IV bolus followed by doses of 10-20 mcg, or as a continuous infusion of 1-20 mcg/min based on heart rate response, according to guidelines from the American College of Cardiology 2, 3
- The short half-life necessitates careful titration and continuous monitoring, as effects dissipate rapidly upon cessation of infusion, as recommended by the American College of Cardiology 2, 3